^
Association details:
| Biomarker: | EGFR S752_I759del |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study
Excerpt:
This open-label phase II trial enrolled stage III/IV NSCLC patients who had progressive disease after at least one prior platinum-based chemotherapy regimen. Erlotinib was administered at a dose of 150 mg/d orally until disease progression or intolerable toxicity....Three patients who had deletion mutations on exon 19 (del E746-A750 or del S752-I759) exhibited objective response.
DOI:
https://doi.org/10.1097/JTO.0b013e31818d6702
